Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.59
QGEN's Cash to Debt is ranked higher than
58% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. QGEN: 0.59 )
QGEN' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 0.59

Equity to Asset 0.61
QGEN's Equity to Asset is ranked higher than
71% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. QGEN: 0.61 )
QGEN' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.72
Current: 0.61

0.44
0.72
Interest Coverage 2.05
QGEN's Interest Coverage is ranked lower than
55% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. QGEN: 2.05 )
QGEN' s 10-Year Interest Coverage Range
Min: 2.05   Max: 53.96
Current: 2.05

2.05
53.96
F-Score: 8
Z-Score: 2.92
M-Score: -2.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.99
QGEN's Operating margin (%) is ranked higher than
90% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. QGEN: 12.99 )
QGEN' s 10-Year Operating margin (%) Range
Min: 4.86   Max: 23.8
Current: 12.99

4.86
23.8
Net-margin (%) 11.21
QGEN's Net-margin (%) is ranked higher than
92% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. QGEN: 11.21 )
QGEN' s 10-Year Net-margin (%) Range
Min: 5.31   Max: 15.62
Current: 11.21

5.31
15.62
ROE (%) 5.59
QGEN's ROE (%) is ranked higher than
76% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. QGEN: 5.59 )
QGEN' s 10-Year ROE (%) Range
Min: 2.51   Max: 20.03
Current: 5.59

2.51
20.03
ROA (%) 3.49
QGEN's ROA (%) is ranked higher than
80% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. QGEN: 3.49 )
QGEN' s 10-Year ROA (%) Range
Min: 1.67   Max: 13.64
Current: 3.49

1.67
13.64
ROC (Joel Greenblatt) (%) 25.81
QGEN's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. QGEN: 25.81 )
QGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.49   Max: 47.81
Current: 25.81

9.49
47.81
Revenue Growth (%) 5.30
QGEN's Revenue Growth (%) is ranked higher than
74% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. QGEN: 5.30 )
QGEN' s 10-Year Revenue Growth (%) Range
Min: -1.8   Max: 43
Current: 5.3

-1.8
43
EBITDA Growth (%) -8.90
QGEN's EBITDA Growth (%) is ranked higher than
66% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. QGEN: -8.90 )
QGEN' s 10-Year EBITDA Growth (%) Range
Min: -8.9   Max: 52.7
Current: -8.9

-8.9
52.7
EPS Growth (%) -22.00
QGEN's EPS Growth (%) is ranked higher than
63% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. QGEN: -22.00 )
QGEN' s 10-Year EPS Growth (%) Range
Min: -22   Max: 60.8
Current: -22

-22
60.8
» QGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

QGEN Guru Trades in Q4 2013

Steven Cohen 9,222 sh (New)
PRIMECAP Management 19,385,944 sh (+8.41%)
Manning & Napier Advisors, Inc 6,290,930 sh (+0.34%)
Ron Baron 10,200 sh (-49%)
» More
Q1 2014

QGEN Guru Trades in Q1 2014

Jim Simons 1,028,319 sh (New)
PRIMECAP Management 22,234,504 sh (+14.69%)
Ron Baron Sold Out
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 4,407,790 sh (-29.93%)
» More
Q2 2014

QGEN Guru Trades in Q2 2014

PRIMECAP Management 22,087,404 sh (-0.66%)
Manning & Napier Advisors, Inc 2,251,855 sh (-48.91%)
Jim Simons 372,000 sh (-63.82%)
» More
Q3 2014

QGEN Guru Trades in Q3 2014

PRIMECAP Management 22,080,114 sh (-0.03%)
Manning & Napier Advisors, Inc 2,226,305 sh (-1.13%)
Jim Simons 217,000 sh (-41.67%)
» More
» Details

Insider Trades

Latest Guru Trades with QGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 Sold Out $20.46 - $24.82 $ 23.936%0
Ron Baron 2013-12-31 Reduce -49%$20.63 - $24.65 $ 23.936%10200
PRIMECAP Management 2013-09-30 Add 60.33%0.19%$19.72 - $21.88 $ 23.9315%17881461
PRIMECAP Management 2013-06-30 Add 22.63%0.06%$18.45 - $21.08 $ 23.9323%11152875
Ron Baron 2013-06-30 Reduce -45.95%$18.45 - $21.08 $ 23.9323%20000
PRIMECAP Management 2012-09-30 Add 31.89%0.06%$16.09 - $18.97 $ 23.9336%8579261
PRIMECAP Management 2012-06-30 New Buy0.18%$15 - $17.22 $ 23.9347%6504966
Ron Baron 2012-03-31 Add 26.98%$14.49 - $16.76 $ 23.9366%40000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 40.80
QGEN's P/E(ttm) is ranked higher than
83% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 40.80 )
QGEN' s 10-Year P/E(ttm) Range
Min: 23.33   Max: 154.48
Current: 40.8

23.33
154.48
P/B 2.10
QGEN's P/B is ranked higher than
86% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. QGEN: 2.10 )
QGEN' s 10-Year P/B Range
Min: 1.19   Max: 2.37
Current: 2.1

1.19
2.37
P/S 4.60
QGEN's P/S is ranked higher than
69% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. QGEN: 4.60 )
QGEN' s 10-Year P/S Range
Min: 2.81   Max: 5.29
Current: 4.6

2.81
5.29
PFCF 56.10
QGEN's PFCF is ranked higher than
55% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 56.10 )
QGEN' s 10-Year PFCF Range
Min: 19.77   Max: 56.6
Current: 56.1

19.77
56.6
EV-to-EBIT 37.35
QGEN's EV-to-EBIT is ranked higher than
79% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 37.35 )
QGEN' s 10-Year EV-to-EBIT Range
Min: 17.8   Max: 102.4
Current: 37.35

17.8
102.4
Shiller P/E 49.20
QGEN's Shiller P/E is ranked higher than
89% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 49.20 )
QGEN' s 10-Year Shiller P/E Range
Min: 24.16   Max: 50.89
Current: 49.2

24.16
50.89
Current Ratio 2.91
QGEN's Current Ratio is ranked higher than
76% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. QGEN: 2.91 )
QGEN' s 10-Year Current Ratio Range
Min: 1.45   Max: 6.29
Current: 2.91

1.45
6.29
Quick Ratio 2.61
QGEN's Quick Ratio is ranked higher than
75% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. QGEN: 2.61 )
QGEN' s 10-Year Quick Ratio Range
Min: 1.18   Max: 5.75
Current: 2.61

1.18
5.75

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.77
QGEN's Price/Tangible Book is ranked higher than
61% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.28 vs. QGEN: 33.77 )
QGEN' s 10-Year Price/Tangible Book Range
Min: 9.13   Max: 117.83
Current: 33.77

9.13
117.83
Price/DCF (Projected) 1.76
QGEN's Price/DCF (Projected) is ranked higher than
90% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 1.76 )
QGEN' s 10-Year Price/DCF (Projected) Range
Min: 1.02   Max: 1.87
Current: 1.76

1.02
1.87
Price/Median PS Value 1.16
QGEN's Price/Median PS Value is ranked higher than
77% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. QGEN: 1.16 )
QGEN' s 10-Year Price/Median PS Value Range
Min: 0.74   Max: 1.28
Current: 1.16

0.74
1.28
Price/Graham Number 7.76
QGEN's Price/Graham Number is ranked higher than
82% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 7.76 )
QGEN' s 10-Year Price/Graham Number Range
Min: 3.6   Max: 16.78
Current: 7.76

3.6
16.78
Earnings Yield (Greenblatt) 2.70
QGEN's Earnings Yield (Greenblatt) is ranked higher than
78% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. QGEN: 2.70 )
QGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 5.6
Current: 2.7

1
5.6
Forward Rate of Return (Yacktman) -0.91
QGEN's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. QGEN: -0.91 )
QGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.4   Max: 13.2
Current: -0.91

-2.4
13.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0H1Z.UK, QIA.Germany
Qiagen NV provides Sample & Assay Technologies, based on market studies of United States and European market shares for its products and technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics. The Company markets more than 500 core products that are distributed in thousands of variations and combinations. In October 2012, the company announced a collaboration with Bayer HealthCare for development and commercialization of companion diagnostics paired with novel Bayer drugs, initially to enhance the treatment of various solid tumors. The Company has developed and advanced a broad range of technologies to extract and purify molecules of interest from biological samples such as blood, bone, tissue. It has also developed assays that enable the analysis of various kinds of molecules from virtually any biological sample. Assay technologies make information contained in isolated molecules visible and available for interpretation. The Company sells varied and flexible workflows for molecular testing, including sample and assay kits known as consumables and automated instrumentation platforms using those technologies, to four major customer classes: Molecular Diagnostics - healthcare providers supporting many aspects of patient care including prevention, profiling of diseases, personalized healthcare and point of need testing; Applied Testing - government or industry customers using molecular technologies in fields such as forensics, veterinary diagnostics and food safety testing; Pharma - drug discovery, translational medicine and clinical development efforts of pharmaceutical and biotechnology companies; Academia - researchers exploring the secrets of life such as the mechanisms and pathways of diseases. The Company markets its products in more than 100 countries throughout the world. The Company's competitors includes Promega Corp., EMD Millipore or Merck Millipore, and Macherey-Nagel GmbH for nucleic acid separation and purification; Thermo Fisher and Promega Corp. for assay solutions and for transfection reagents; and Sigma-Aldrich Corp. and Thermo Fisher for protein fractionation products. The Company is subject to a variety of laws and regulations in the European Union, the United States and other countries.
» More Articles for QGEN

Headlines

Articles On GuruFocus.com
comment on QGEN May 14 2013 
comment on QGEN May 10 2013 
Biotech Gets Personal: Long on Qiagen (QGEN) & SPDR S&P Biotech (XBI) Feb 29 2012 
Guru Stocks at 52-Week Lows: LMT, VIP, VMC, IRM, QGEN Oct 10 2010 
Weekly Guru Bargains Highlights: QGEN, BXS, ATHR, LYV, TFSL Oct 09 2010 

More From Other Websites
Qiagen Partners with Novartis for Companion Diagnostics Nov 13 2014
QIAGEN signs ninth master collaboration agreement for companion diagnostics Nov 11 2014
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics Nov 11 2014
Qiagen Q3 Earnings, Revenues in Line; Outlook Revised Oct 30 2014
Qiagen meets 3Q profit forecasts Oct 29 2014
Qiagen meets 3Q profit forecasts Oct 29 2014
QIAGEN reports results for third quarter and first nine months of 2014 Oct 29 2014
QIAGEN Reports Results for Third Quarter and First Nine Months of 2014 Oct 29 2014
Can Qiagen (QGEN) Surprise Earnings Estimates in Q3? Oct 28 2014
QIAGEN announces broad agreement with Astellas Pharma to develop companion diagnostics Oct 28 2014
QIAGEN Announces Broad Agreement With Astellas Pharma to Develop Companion Diagnostics Oct 28 2014
QIAGEN Applauds Inclusion of Screening and Treatment for Latent Infection in WHO's Post-2015 Global... Oct 28 2014
QIAGEN demonstrates expanded bioinformatics workflows at ASHG; strong market adoption as researchers... Oct 17 2014
QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers... Oct 17 2014
Genomics England names QIAGEN Bioinformatics one of the UK100K project assessment winners Oct 14 2014
Genomics England Names QIAGEN Bioinformatics One of the UK100K Project Assessment Winners Oct 14 2014
Genomics England Names QIAGEN Bioinformatics One of the UK100K Project Assessment Winners Oct 14 2014
QIAGEN N.V. to Report Third Quarter 2014 Results and Hold Webcast Oct 10 2014
Qiagen's Molecular Diagnostics, Global Market Show Strength Sep 26 2014
3 Stocks Pushing The Diversified Services Industry Downward Sep 26 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK